NEW YORK and LONDON, Feb. 05, 2021 (GLOBE NEWSWIRE) Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ( Tiziana or the Company ), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the appointment of Dr. Thomas Adams, Ph.D. as an executive director.
Dr. Adams will assume the position of Head of Drug Development with immediate effect and his executive role will be to manage and oversee all matters relating to the Company s pre-clinical and clinical drug development programs and associated intellectual property.
Dr. Thomas H. Adams (age: 78)
Dr. Adams holds a Ph.D. in Biochemistry from the University of California, Riverside. The Board believes that Dr. Adams executive leadership and the extensive healthcare expertise he has developed makes Dr. Adams ideally qualified to serve as an additional director of the Company.
Search jobs Constipation Treatment Market :Global Analysis and Opportunity Assessment 2021-2026- Market.biz
Pune, Maharashtra, India, January 29 2021 (Wiredrelease) MarketDesk –:The Global Constipation Treatment Market 2021 covers explicit data related to the development rate, market estimates, drivers, limitations, future based demand, and revenue during the forecast period 2021-2026. The Global Constipation Treatment Market contained accumulated data from various primary and secondary sources. This information has been verified and validated by the market analysts, thus providing significant insights to the researchers, experts, managers, and other industry professionals. This document further helps in understanding market development, applications, specifications, and market challenges.
This research study owns a very wide scope as its application can aid the client in knowing the industry in detail, the reader will probably find that this record mak
Press release content from Wired Release. The AP news staff was not involved in its creation.
Chronic Idiopathic Constipation (Cic) Drugs Market by Manufacturers,Revenue,Trend and Forecast Report 2021-2026- Market.biz
January 29, 2021 GMT
Pune, Maharashtra, India, January 29 2021 (Wiredrelease) MarketDesk :The Global Chronic Idiopathic Constipation (Cic) Drugs Market 2021 covers explicit data related to the development rate, market estimates, drivers, limitations, future based demand, and revenue during the forecast period 2021-2026. The Global Chronic Idiopathic Constipation (Cic) Drugs Market contained accumulated data from various primary and secondary sources. This information has been verified and validated by the market analysts, thus providing significant insights to the researchers, experts, managers, and other industry professionals. This document further helps in understanding market development, applications, specifications, and market challenges.
Ellodi Pharmaceuticals Welcomes Dr. David Kessler and John Fraher to its Board of Directors
Ellodi Pharmaceuticals Welcomes Dr. David Kessler and John Fraher to its Board of Directors Ellodi Pharmaceuticals, a gastroenterology-focused specialty pharmaceutical company formed by TPG Capital, today announced that David Kessler, M.D., and John Fraher have joined the companys newly established Board of Directors. Dr. Kessler and Fraher will serve on the companys inaugural board alongside CEO Troy Hamilton and three members of the TPG Capital team: John Schilling, M.D., Todd Sisitsky, and Katherine Wood. The formation of the board follows the recent creation of Ellodi Pharmaceuticals, which was established in September 2020 through a transaction that spun-out select clinical assets from Adare Pharmaceuticals. Launched in partnership with former members of Adares clinical leadership team, Ellodi Pharmaceuticals is dedicated to the continued development of APT-1011, a novel therapy in
7 January 2021
OKYO Pharma Limited ( OKYO or the Company ) today announces that Gabriele Cerrone has been appointed as a non-executive chairman of the company and Dr Gary S. Jacob has been appointed as Chief Executive Officer and director of the company, both with immediate effect. Gabriele Cerrone (age: 48) Mr Cerrone has a successful track record and extensive experience in the financing and restructuring of micro-cap biotechnology companies. He has founded ten biotechnology companies in oncology, infectious diseases and molecular diagnostics, and has taken seven of these companies to the NASDAQ Market and two to the Main Market and AIM Market in London. Mr Cerrone is Executive Chairman of dual listed Tiziana Life Sciences plc. Mr Cerrone co-founded Cardiff Oncology, Inc. (NASDAQ: CRDF), an oncology company and served as its Co-Chairman; he was a co-founder and served as Chairman of both Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) and Callisto Pharmaceutical